Menu Search
Equities

Axonics Inc

AXNX:NSQ

Axonics Inc

Actions
Health CareMedical Equipment and Services
  • Price (USD)69.25
  • Today's Change0.530 / 0.77%
  • Shares traded596.78k
  • 1 Year change+18.74%
  • Beta0.8241
Data delayed at least 15 minutes, as of Sep 19 2024 21:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 14-Sep-23
  • 20-Jun-24
  • 18-Jul-24
  • 15-Aug-24
  • 12-Sep-24
Select bar for recommendation details.
Recommendations12-Sep-24
Buy0
Outperform1
Hold12
Sell0
Strong Sell0

Share price forecast in USD

The 11 analysts offering 12 month price targets for Axonics Inc have a median target of 71.00, with a high estimate of 75.00 and a low estimate of 71.00. The median estimate represents a 2.53% increase from the last price of 69.25.
High8.3%75.00
Med2.5%71.00
Low2.5%71.00

Earnings history & estimates in USD

On Aug 01, 2024, Axonics Inc reported 2nd quarter 2024 earnings of 0.13 per share. This result was in line with the consensus of the 8 analysts following the company and outperformed last year's 2nd quarter results by 0.28.
The next earnings announcement is expected on Oct 28, 2024.
Average growth rate+62.50%
Axonics Inc reported annual 2023 losses of -0.12 per share on Feb 28, 2024.
Average growth rate+35.82%
More ▼

Revenue history & estimates in USD

Axonics Modulation Technologies, Inc. had 2nd quarter 2024 revenues of 114.57m. This bettered the 112.27m consensus of the 8 analysts covering the company. This was 62.16% above the prior year's 2nd quarter results.
Average growth rate+6.68%
Axonics Modulation Technologies, Inc. had revenues for the full year 2023 of 366.38m. This was 33.86% above the prior year's results.
Average growth rate+213.59%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.